Rituximab Treatment of Patients with Severe, Corticosteroid-Resistant Thyroid-Associated Ophthalmopathy
- 1 January 2010
- journal article
- Published by Elsevier in Ophthalmology
- Vol. 117 (1) , 133-139.e2
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- The incidence of autoimmune thyroid disease: a systematic review of the literatureClinical Endocrinology, 2008
- Unique Attributes of Orbital Fibroblasts and Global Alterations in IGF-1 Receptor Signaling Could Explain Thyroid-Associated OphthalmopathyThyroid®, 2008
- How regulatory T cells workNature Reviews Immunology, 2008
- Improvement in patient‐reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti–tumor necrosis factor therapyArthritis Care & Research, 2008
- Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker resultsAnnals of the Rheumatic Diseases, 2008
- Levels of autoantibodies, unlike antibodies to all extrinsic antigen groups, fall following B cell depletion with RituximabEuropean Journal of Immunology, 2007
- Consensus statement on the use of rituximab in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2007
- Circulating mononuclear cells from euthyroid patients with thyroid-associated ophthalmopathy exhibit characteristic phenotypesClinical and Experimental Immunology, 2007
- Medial Wall Decompression For Optic Neuropathy But Lateral Wall Decompression With Fat Removal For Non Vision-Threatening IndicationsAmerican Journal of Ophthalmology, 2006
- The rationale for B lymphocyte depletion in Graves’ disease. Monoclonal anti-CD20 antibody therapy as a novel treatment optionEuropean Journal of Endocrinology, 2006